With ovarian cancer continuing to have a devastating outcome for many women, new research at the Kolling Institute is offering hope. The disease has the lowest survival rate of any women’s cancer, with only 48 per cent of women living beyond five years after diagnosis. Ovarian cancer is often diagnosed late because the symptoms are vague, like bloating, nausea, indigestion, excessive tir.....
Read more

Generous funding provided through the Douglas and Lola Douglas scholarship is strengthening evidence around the long term impacts on children born to mothers with obesity and gestational diabetes. Endocrinologist and Kolling Institute researcher Dr Tessa Weir has been able to continue her valuable research as a result of being awarded the scholarship. “I am incredibly grateful for t.....
Read more

Kolling researcher and Royal North Shore Hospital endocrinologist Associate Professor Sarah Glastras will have a key role in a national effort to improve long-term outcomes for those with diabetes. The initiative has brought dozens of experts from across the country together under the banner of the Australian Centre for Accelerating Diabetes Innovations Research. International collaborat.....
Read more

Improved accessibility to a treatment for kidney disease has been welcomed by Kolling Institute researcher and Royal North Shore Hospital clinician Professor Carol Pollock. Forxiga (dapagliflozin), an oral medicine which can help slow the progression of proteinuric chronic kidney disease, has now been listed on the Pharmaceutical Benefits Scheme. The listing aims to help those with the c.....
Read more

Our researchers are seeking participants for a large-scale clinical trial pioneering the use of stem cells to treat and potentially cure osteoarthritis. The disease is now one of the leading causes of disability in the world, affecting around three million people in Australia alone. Royal North Shore Hospital rheumatologist Professor David Hunter is leading the two-year trial which is re.....
Read more

New funding will see a large-scale project launched across NSW to significantly improve patient outcomes and experiences in Emergency Departments. Chief investigator and Kolling Institute researcher Professor Margaret Fry said more than $2.8 million will be invested in the EPIC-START program, giving patients better access to early evidence-based treatment pathways. 30 Emergency Departmen.....
Read more

Clinicians, researchers and patients have welcomed a landmark law which will pave the way for remarkable new IVF technology to prevent mitochondrial disease. Known as “Maeve’s law” after a young Victorian girl with a rare genetic disorder, the legislation was passed by Federal Parliament allowing the specialised IVF procedure to be carried out in Australia. It will involve replacing faul.....
Read more

With large numbers of people across the community looking for effective and lasting ways to treat pain, our researchers at the Kolling Institute are driving nationally significant projects to reduce a reliance on opioid medication and promote proven alternative options. The research by our team from the Pain Management Research Centre follows the latest figures which indicate around 20 p.....
Read more

A team from the Kolling Institute led by Professor Sarah Hilmer has helped develop a valuable, new national program to reduce the adverse impacts of taking multiple medicines. Medicines with an anticholinergic effect can successfully treat many conditions such as depression, dementia and chronic non-cancer pain. Cumulatively however, they can cause serious adverse effects such as falls, .....
Read more

An important new partnership has been formed to dramatically improve care for musculoskeletal conditions by speeding up the translation of research to clinical practice. The Northern Sydney Local Health District has joined with the University of Sydney and Sydney Local Health District to create Sydney Musculoskeletal Health which will link researchers from across the University with clin.....
Read more